| Alterations in plasma nitric oxide level and arginase activity during the treatment of bipolar depressive episode | Nurdan Özlü CEYLAN, İclal Geyikli ÇİMENCİ, Ayşe KILINÇASLAN, Feridun BÜLBÜL, Haluk A. SAVAŞ | 1–6 |
| Comorbid disorders in outpatients with major depressive disorder and their sociodemographical aspects | Şadiye Visal Buturak, Ayşe Devrim BAŞTERZİ, Aylin YAZICI, Kemal YAZICI, Şenel Tot Acar | 7–13 |
| Lipid peroxidation and serum antioxidant enzymes activity in patients with bipolar and major depressive disorders | Murat Can, Berrak Güven, Levent Atik, Numan KONUK | 14–18 |
| Lack of association between COMT gene polymorphism and treatment outcome in major depression | Salih SELEK, Mehmet C. KAYA, Mehmet Emin ERDAL, Mahmut BULUT, Murat Eren OZEN, Mehmet YUMRU, Ömer BARLAS, Aysun KALENDEROGLU, Hasan HERKEN | 19–24 |
| The comorbidity of migraine in bipolar disorder | Aslihan Okan IBİLOGLU, Ali CAYKOYLU | 25–33 |
| Pharmacotherapy of child and adolescent depression: a review | Mustafa Deniz TUTKUNKARDAŞ, Ayşe KILINÇASLAN | 34–45 |
| What do we be after? Holy p value (statistical significance) or clinical significance? | Selim KILIÇ | 46–48 |